p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
23 05 2022
Historique:
received: 30 03 2021
accepted: 29 04 2022
entrez: 23 5 2022
pubmed: 24 5 2022
medline: 26 5 2022
Statut: epublish

Résumé

Current therapy against colorectal cancer (CRC) is based on DNA-damaging agents that remain ineffective in a proportion of patients. Whether and how non-curative DNA damage-based treatment affects tumor cell behavior and patient outcome is primarily unstudied. Using CRC patient-derived organoids (PDO)s, we show that sublethal doses of chemotherapy (CT) does not select previously resistant tumor populations but induces a quiescent state specifically to TP53 wildtype (WT) cancer cells, which is linked to the acquisition of a YAP1-dependent fetal phenotype. Cells displaying this phenotype exhibit high tumor-initiating and metastatic activity. Nuclear YAP1 and fetal traits are present in a proportion of tumors at diagnosis and predict poor prognosis in patients carrying TP53 WT CRC tumors. We provide data indicating the higher efficacy of CT together with YAP1 inhibitors for eradication of therapy resistant TP53 WT cancer cells. Together these results identify fetal conversion as a useful biomarker for patient prognosis and therapy prescription.

Identifiants

pubmed: 35606354
doi: 10.1038/s41467-022-30382-9
pii: 10.1038/s41467-022-30382-9
pmc: PMC9126967
doi:

Substances chimiques

TP53 protein, human 0
Tumor Suppressor Protein p53 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2866

Informations de copyright

© 2022. The Author(s).

Références

J Clin Invest. 2018 Aug 31;128(9):3887-3905
pubmed: 29944140
Genome Biol. 2014;15(12):550
pubmed: 25516281
Microcirculation. 2000 Dec;7(6 Pt 1):405-10
pubmed: 11142337
Cell Stem Cell. 2018 Jan 4;22(1):35-49.e7
pubmed: 29249464
EMBO J. 2012 Jun 12;31(14):3079-91
pubmed: 22692129
Nat Commun. 2011 Jan 18;2:162
pubmed: 21245843
Clin Cancer Res. 2009 Dec 15;15(24):7642-7651
pubmed: 19996206
Lancet. 2014 Apr 26;383(9927):1490-1502
pubmed: 24225001
Mol Cancer Res. 2015 Jan;13(1):16-28
pubmed: 25158956
Nat Commun. 2020 Oct 21;11(1):5321
pubmed: 33087710
Cell Stem Cell. 2020 Jun 4;26(6):845-861.e12
pubmed: 32396863
Cancer Res. 2010 Dec 15;70(24):10464-73
pubmed: 21159656
Mol Cell. 2016 Jul 7;63(1):156-66
pubmed: 27292796
Mol Cell. 2020 Oct 15;80(2):183-192
pubmed: 32946743
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Cell. 2017 Jun 1;169(6):1000-1011
pubmed: 28575665
Front Oncol. 2013 Aug 15;3:211
pubmed: 23967403
Bioinformatics. 2018 May 1;34(9):1600-1602
pubmed: 29069305
PLoS Med. 2013;10(5):e1001453
pubmed: 23700391
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Cell Rep. 2013 Oct 31;5(2):421-32
pubmed: 24139799
Nat Rev Cancer. 2019 Aug;19(8):439-453
pubmed: 31235879
J Clin Invest. 2014 Feb;124(2):528-42
pubmed: 24382349
Cancer Cell. 2018 Jun 11;33(6):1094-1110.e8
pubmed: 29805078
Science. 2013 Feb 1;339(6119):543-8
pubmed: 23239622
Nature. 2017 Mar 29;543(7647):676-680
pubmed: 28358093
Nat Med. 2017 Oct 6;23(10):1124-1134
pubmed: 28985214
Nature. 2018 Jan 4;553(7686):96-100
pubmed: 29258294
Nat Genet. 2020 Jun;52(6):594-603
pubmed: 32451460
Clin Cancer Res. 2014 Feb 15;20(4):837-46
pubmed: 24323901
Cell Stem Cell. 2020 Apr 2;26(4):569-578.e7
pubmed: 32169167
Mol Cell. 2019 Aug 22;75(4):669-682.e5
pubmed: 31302002
Nat Med. 2018 Aug;24(8):1246-1256
pubmed: 29988130
Cell Stem Cell. 2011 May 6;8(5):511-24
pubmed: 21419747
Cell Stem Cell. 2020 Oct 1;27(4):590-604.e9
pubmed: 32730753
Cell. 1995 May 5;81(3):323-30
pubmed: 7736585
Front Oncol. 2017 Nov 23;7:278
pubmed: 29218300
Nature. 2015 Oct 29;526(7575):715-8
pubmed: 26503053
Oncotarget. 2016 May 3;7(18):25478-92
pubmed: 27009858
Nature. 2018 Jul;559(7712):109-113
pubmed: 29950724
Cell Stem Cell. 2017 Feb 2;20(2):233-246.e7
pubmed: 27989769
Cancer Res. 2019 Mar 15;79(6):1044-1046
pubmed: 30803994
Cancer Res. 2018 Nov 1;78(21):6320-6328
pubmed: 30232219
Cancers (Basel). 2018 Apr 10;10(4):
pubmed: 29642615
Cell. 2021 Jan 7;184(1):226-242.e21
pubmed: 33417860
Cell Stem Cell. 2017 Nov 2;21(5):650-664.e8
pubmed: 29100014

Auteurs

Laura Solé (L)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain.
CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.

Teresa Lobo-Jarne (T)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain.
CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.

Daniel Álvarez-Villanueva (D)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain.
Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.

Josune Alonso-Marañón (J)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain.

Yolanda Guillén (Y)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain.

Marta Guix (M)

Department of Oncology, Institut Mar d'Investigacions Mèdiques, CIBERONC, Universitat Pompeu Fabra, Barcelona, 08003, Spain.

Irene Sangrador (I)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain.

Catalina Rozalén (C)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain.

Anna Vert (A)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain.

Antonio Barbachano (A)

CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
Department of Cancer Biology, Instituto de Investigaciones Biomédicas 'Alberto Sols', Spanish National Research Council (CSIC)-Autonomous University of Madrid (UAM) and IdiPAZ, Madrid, Spain.

Joan Lop (J)

Department of Pathology, Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona, Barcelona, 08003, Spain.

Marta Salido (M)

Department of Pathology, Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona, Barcelona, 08003, Spain.

Beatriz Bellosillo (B)

CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
Department of Pathology, Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona, Barcelona, 08003, Spain.

Raquel García-Romero (R)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain.

Marta Garrido (M)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain.

Jessica González (J)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain.

María Martínez-Iniesta (M)

Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.

Erika López-Arribillaga (E)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain.
Group of Biomedical Genomics, Institut de Recerca Biomedica (IRB), Barcelona, 08028, Spain.

Ramón Salazar (R)

CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.

Clara Montagut (C)

CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
Department of Oncology, Institut Mar d'Investigacions Mèdiques, CIBERONC, Universitat Pompeu Fabra, Barcelona, 08003, Spain.

Ferrán Torres (F)

Biostatistics Unit, Medical School, Universitat Autònoma de Barcelona, Barcelona, Spain.

Mar Iglesias (M)

CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
Department of Pathology, Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona, Barcelona, 08003, Spain.

Toni Celià-Terrassa (T)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain.

Alberto Muñoz (A)

CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
Department of Cancer Biology, Instituto de Investigaciones Biomédicas 'Alberto Sols', Spanish National Research Council (CSIC)-Autonomous University of Madrid (UAM) and IdiPAZ, Madrid, Spain.

Alberto Villanueva (A)

Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.

Anna Bigas (A)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain. abigas@imim.es.
CIBERONC, Instituto de Salud Carlos III, Madrid, Spain. abigas@imim.es.

Lluís Espinosa (L)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain. lespinosa@imim.es.
CIBERONC, Instituto de Salud Carlos III, Madrid, Spain. lespinosa@imim.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH